APO Research
Talk to an analyst

APO RESEARCH · REPORT

Prophylactic Human Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Prophylactic Human Vaccine Industry Growth and Trends Forecast to 2032

26 December 202593 pages

Choose your research edition.

Industry ResearchProphylactic Human Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Prophylactic Human Vaccine Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Prophylactic Human Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Prophylactic Human Vaccine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Prophylactic Human Vaccine Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Prophylactic Human Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Prophylactic Human Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Prophylactic Human Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Prophylactic Human Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Prophylactic Human Vaccine include GSK, Sanofi, Merck, Zoetis, Merial, McKesson Medical and Biovac, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Prophylactic Human Vaccine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Prophylactic Human Vaccine market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Prophylactic Human Vaccine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Prophylactic Human Vaccine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Prophylactic Human Vaccine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Prophylactic Human Vaccine Market by Company

GSK

Sanofi

Merck

Zoetis

Merial

McKesson Medical

Biovac

Prophylactic Human Vaccine Segment by Type

Inactivated Vaccine

Attenuated Vaccine

Others

Prophylactic Human Vaccine Segment by Application

Hospital

Scientific Research

Others

Prophylactic Human Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prophylactic Human Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Prophylactic Human Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prophylactic Human Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Prophylactic Human Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Prophylactic Human Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Inactivated Vaccine Table 2. Major Company of Attenuated Vaccine Table 3. Major Company of Others Table 4. Global Prophylactic Human Vaccine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Prophylactic Human Vaccine Sales by Type (2021-2026) & (K Units) Table 6. Global Prophylactic Human Vaccine Sales Market Share in Volume by Type (2021-2026) Table 7. Global Prophylactic Human Vaccine Sales by Type (2021-2026) & (US$ Million) Table 8. Global Prophylactic Human Vaccine Sales Market Share in Value by Type (2021-2026) Table 9. Global Prophylactic Human Vaccine Price by Type (2021-2026) & (US$/Unit) Table 10. Global Prophylactic Human Vaccine Sales by Type (2027-2032) & (K Units) Table 11. Global Prophylactic Human Vaccine Sales Market Share in Volume by Type (2027-2032) Table 12. Global Prophylactic Human Vaccine Sales by Type (2027-2032) & (US$ Million) Table 13. Global Prophylactic Human Vaccine Sales Market Share in Value by Type (2027-2032) Table 14. Global Prophylactic Human Vaccine Price by Type (2027-2032) & (US$/Unit) Table 15. North America Prophylactic Human Vaccine Sales by Type (2021-2026) & (K Units) Table 16. North America Prophylactic Human Vaccine Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Prophylactic Human Vaccine Sales by Type (2021-2026) & (K Units) Table 18. Europe Prophylactic Human Vaccine Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Prophylactic Human Vaccine Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific Prophylactic Human Vaccine Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Prophylactic Human Vaccine Sales by Type (2021-2026) & (K Units) Table 22. Latin America Prophylactic Human Vaccine Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Prophylactic Human Vaccine Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa Prophylactic Human Vaccine Sales by Type (2021-2026) & (US$ Million) Table 25. Prophylactic Human Vaccine Industry Trends Table 26. Prophylactic Human Vaccine Industry Drivers Table 27. Prophylactic Human Vaccine Industry Opportunities and Challenges Table 28. Prophylactic Human Vaccine Industry Restraints Table 29. Global Prophylactic Human Vaccine Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Prophylactic Human Vaccine Revenue Market Share by Company (2021-2026) Table 31. Global Prophylactic Human Vaccine Sales by Company (2021-2026) & (K Units) Table 32. Global Prophylactic Human Vaccine Sales Share by Company (2021-2026) Table 33. Global Prophylactic Human Vaccine Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Prophylactic Human Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Prophylactic Human Vaccine Major Company Production Sites and Headquarters Table 36. Global Prophylactic Human Vaccine Company, Product Type & Application Table 37. Global Prophylactic Human Vaccine Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Prophylactic Human Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Prophylactic Human Vaccine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Prophylactic Human Vaccine Sales by Region (2021-2026) & (K Units) Table 42. Global Prophylactic Human Vaccine Sales Market Share in Volume by Region (2021-2026) Table 43. Global Prophylactic Human Vaccine Sales by Region (2021-2026) & (US$ Million) Table 44. Global Prophylactic Human Vaccine Sales Market Share in Value by Region (2021-2026) Table 45. Global Prophylactic Human Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Prophylactic Human Vaccine Sales by Region (2027-2032) & (K Units) Table 47. Global Prophylactic Human Vaccine Sales Market Share in Volume by Region (2027-2032) Table 48. Global Prophylactic Human Vaccine Sales by Region (2027-2032) & (US$ Million) Table 49. Global Prophylactic Human Vaccine Sales Market Share in Value by Region (2027-2032) Table 50. Global Prophylactic Human Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Prophylactic Human Vaccine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Prophylactic Human Vaccine Sales by Application (2021-2026) & (K Units) Table 53. Global Prophylactic Human Vaccine Sales Market Share in Volume by Application (2021-2026) Table 54. Global Prophylactic Human Vaccine Sales by Application (2021-2026) & (US$ Million) Table 55. Global Prophylactic Human Vaccine Sales Market Share in Value by Application (2021-2026) Table 56. Global Prophylactic Human Vaccine Price by Application (2021-2026) & (US$/Unit) Table 57. Global Prophylactic Human Vaccine Sales by Application (2027-2032) & (K Units) Table 58. Global Prophylactic Human Vaccine Sales Market Share in Volume by Application (2027-2032) Table 59. Global Prophylactic Human Vaccine Sales by Application (2027-2032) & (US$ Million) Table 60. Global Prophylactic Human Vaccine Sales Market Share in Value by Application (2027-2032) Table 61. Global Prophylactic Human Vaccine Price by Application (2027-2032) & (US$/Unit) Table 62. North America Prophylactic Human Vaccine Sales by Application (2021-2026) & (K Units) Table 63. North America Prophylactic Human Vaccine Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Prophylactic Human Vaccine Sales by Application (2021-2026) & (K Units) Table 65. Europe Prophylactic Human Vaccine Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Prophylactic Human Vaccine Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific Prophylactic Human Vaccine Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Prophylactic Human Vaccine Sales by Application (2021-2026) & (K Units) Table 69. Latin America Prophylactic Human Vaccine Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Prophylactic Human Vaccine Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa Prophylactic Human Vaccine Sales by Application (2021-2026) & (US$ Million) Table 72. GSK Company Information Table 73. GSK Business Overview Table 74. GSK Prophylactic Human Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. GSK Prophylactic Human Vaccine Product Portfolio Table 76. GSK Recent Development Table 77. Sanofi Company Information Table 78. Sanofi Business Overview Table 79. Sanofi Prophylactic Human Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Sanofi Prophylactic Human Vaccine Product Portfolio Table 81. Sanofi Recent Development Table 82. Merck Company Information Table 83. Merck Business Overview Table 84. Merck Prophylactic Human Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Merck Prophylactic Human Vaccine Product Portfolio Table 86. Merck Recent Development Table 87. Zoetis Company Information Table 88. Zoetis Business Overview Table 89. Zoetis Prophylactic Human Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Zoetis Prophylactic Human Vaccine Product Portfolio Table 91. Zoetis Recent Development Table 92. Merial Company Information Table 93. Merial Business Overview Table 94. Merial Prophylactic Human Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Merial Prophylactic Human Vaccine Product Portfolio Table 96. Merial Recent Development Table 97. McKesson Medical Company Information Table 98. McKesson Medical Business Overview Table 99. McKesson Medical Prophylactic Human Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. McKesson Medical Prophylactic Human Vaccine Product Portfolio Table 101. McKesson Medical Recent Development Table 102. Biovac Company Information Table 103. Biovac Business Overview Table 104. Biovac Prophylactic Human Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Biovac Prophylactic Human Vaccine Product Portfolio Table 106. Biovac Recent Development Table 107. North America Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 108. North America Prophylactic Human Vaccine Sales by Country (2021-2026) & (K Units) Table 109. North America Prophylactic Human Vaccine Sales Market Share by Country (2021-2026) Table 110. North America Prophylactic Human Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 111. North America Prophylactic Human Vaccine Sales Market Share Forecast by Country (2027-2032) Table 112. North America Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 113. North America Prophylactic Human Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 114. North America Prophylactic Human Vaccine Market Share by Country (2021-2026) Table 115. North America Prophylactic Human Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 116. North America Prophylactic Human Vaccine Market Share Forecast by Country (2027-2032) Table 117. Europe Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 118. Europe Prophylactic Human Vaccine Sales by Country (2021-2026) & (K Units) Table 119. Europe Prophylactic Human Vaccine Sales Market Share by Country (2021-2026) Table 120. Europe Prophylactic Human Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 121. Europe Prophylactic Human Vaccine Sales Market Share Forecast by Country (2027-2032) Table 122. Europe Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 123. Europe Prophylactic Human Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 124. Europe Prophylactic Human Vaccine Market Share by Country (2021-2026) Table 125. Europe Prophylactic Human Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 126. Europe Prophylactic Human Vaccine Market Share Forecast by Country (2027-2032) Table 127. Asia-Pacific Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 128. Asia-Pacific Prophylactic Human Vaccine Sales by Country (2021-2026) & (K Units) Table 129. Asia-Pacific Prophylactic Human Vaccine Sales Market Share by Country (2021-2026) Table 130. Asia-Pacific Prophylactic Human Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 131. Asia-Pacific Prophylactic Human Vaccine Sales Market Share Forecast by Country (2027-2032) Table 132. Asia-Pacific Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. Asia-Pacific Prophylactic Human Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 134. Asia-Pacific Prophylactic Human Vaccine Market Share by Country (2021-2026) Table 135. Asia-Pacific Prophylactic Human Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. Asia-Pacific Prophylactic Human Vaccine Market Share Forecast by Country (2027-2032) Table 137. Latin America Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 138. Latin America Prophylactic Human Vaccine Sales by Country (2021-2026) & (K Units) Table 139. Latin America Prophylactic Human Vaccine Sales Market Share by Country (2021-2026) Table 140. Latin America Prophylactic Human Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 141. Latin America Prophylactic Human Vaccine Sales Market Share Forecast by Country (2027-2032) Table 142. Latin America Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Latin America Prophylactic Human Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 144. Latin America Prophylactic Human Vaccine Market Share by Country (2021-2026) Table 145. Latin America Prophylactic Human Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Latin America Prophylactic Human Vaccine Market Share Forecast by Country (2027-2032) Table 147. Middle East and Africa Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 148. Middle East and Africa Prophylactic Human Vaccine Sales by Country (2021-2026) & (K Units) Table 149. Middle East and Africa Prophylactic Human Vaccine Sales Market Share by Country (2021-2026) Table 150. Middle East and Africa Prophylactic Human Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 151. Middle East and Africa Prophylactic Human Vaccine Sales Market Share Forecast by Country (2027-2032) Table 152. Middle East and Africa Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Middle East and Africa Prophylactic Human Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 154. Middle East and Africa Prophylactic Human Vaccine Market Share by Country (2021-2026) Table 155. Middle East and Africa Prophylactic Human Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Middle East and Africa Prophylactic Human Vaccine Market Share Forecast by Country (2027-2032) Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Prophylactic Human Vaccine Distributors List Table 160. Prophylactic Human Vaccine Customers List Table 161. Research Programs/Design for This Report Table 162. Authors List of This Report Table 163. Secondary Sources Table 164. Primary Sources List of Figures Figure 1. Prophylactic Human Vaccine Image Figure 2. Global Prophylactic Human Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Prophylactic Human Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Prophylactic Human Vaccine Sales (2021-2032) & (K Units) Figure 5. Inactivated Vaccine Image Figure 6. Global Inactivated Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 7. Attenuated Vaccine Image Figure 8. Global Attenuated Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 9. Others Image Figure 10. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global Prophylactic Human Vaccine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Prophylactic Human Vaccine Market Share by Type 2025 VS 2032 Figure 13. North America Prophylactic Human Vaccine Sales Market Share in Volume by Type in 2025 Figure 14. North America Prophylactic Human Vaccine Sales Market Share in Value by Type in 2025 Figure 15. Europe Prophylactic Human Vaccine Sales Market Share in Volume by Type in 2025 Figure 16. Europe Prophylactic Human Vaccine Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Prophylactic Human Vaccine Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Prophylactic Human Vaccine Sales Market Share in Value by Type in 2025 Figure 19. Latin America Prophylactic Human Vaccine Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Prophylactic Human Vaccine Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Prophylactic Human Vaccine Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Prophylactic Human Vaccine Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Prophylactic Human Vaccine Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Hospital Image Figure 26. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 27. Scientific Research Image Figure 28. Global Scientific Research Sales YoY Growth (2021-2032) & (K Units) Figure 29. Others Image Figure 30. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 31. Global Prophylactic Human Vaccine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Prophylactic Human Vaccine Market Share by Application 2025 VS 2032 Figure 33. North America Prophylactic Human Vaccine Sales Market Share in Volume by Application in 2025 Figure 34. North America Prophylactic Human Vaccine Sales Market Share in Value by Application in 2025 Figure 35. Europe Prophylactic Human Vaccine Sales Market Share in Volume by Application in 2025 Figure 36. Europe Prophylactic Human Vaccine Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Prophylactic Human Vaccine Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Prophylactic Human Vaccine Sales Market Share in Value by Application in 2025 Figure 39. Latin America Prophylactic Human Vaccine Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Prophylactic Human Vaccine Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Prophylactic Human Vaccine Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Prophylactic Human Vaccine Sales Market Share in Value by Application in 2025 Figure 43. North America Prophylactic Human Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. North America Prophylactic Human Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Prophylactic Human Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Prophylactic Human Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Prophylactic Human Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Europe Prophylactic Human Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Prophylactic Human Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Prophylactic Human Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Prophylactic Human Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Asia-Pacific Prophylactic Human Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Prophylactic Human Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Prophylactic Human Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Prophylactic Human Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Latin America Prophylactic Human Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Prophylactic Human Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Prophylactic Human Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Prophylactic Human Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Middle East and Africa Prophylactic Human Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Prophylactic Human Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Prophylactic Human Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Prophylactic Human Vaccine Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Prophylactic Human Vaccine Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Inactivated Vaccine
  • Attenuated Vaccine
  • Others
Applications
  • Hospital
  • Scientific Research
  • Others
Companies covered
  • GSK
  • Sanofi
  • Merck
  • Zoetis
  • Merial
  • McKesson Medical
  • Biovac

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Prophylactic Human Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Prophylactic Human Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Prophylactic Human Vaccine Market by Type
  6. 1.3.1 Inactivated Vaccine
  7. 1.3.2 Attenuated Vaccine
  8. 1.3.3 Others
  9. 1.4 Global Prophylactic Human Vaccine Market Size by Type
  10. 1.4.1 Global Prophylactic Human Vaccine Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Prophylactic Human Vaccine Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Prophylactic Human Vaccine Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Prophylactic Human Vaccine Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Prophylactic Human Vaccine Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Prophylactic Human Vaccine Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Prophylactic Human Vaccine Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Prophylactic Human Vaccine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Prophylactic Human Vaccine Industry Trends
  2. 2.2 Prophylactic Human Vaccine Industry Drivers
  3. 2.3 Prophylactic Human Vaccine Industry Opportunities and Challenges
  4. 2.4 Prophylactic Human Vaccine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Prophylactic Human Vaccine Revenue (2021-2026)
  2. 3.2 Global Top Players by Prophylactic Human Vaccine Sales (2021-2026)
  3. 3.3 Global Top Players by Prophylactic Human Vaccine Price (2021-2026)
  4. 3.4 Global Prophylactic Human Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Prophylactic Human Vaccine Major Company Production Sites & Headquarters
  6. 3.6 Global Prophylactic Human Vaccine Company, Product Type & Application
  7. 3.7 Global Prophylactic Human Vaccine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Prophylactic Human Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Prophylactic Human Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Prophylactic Human Vaccine Tier 1, Tier 2, and Tier 3
4 Prophylactic Human Vaccine Regional Status and Outlook
  1. 4.1 Global Prophylactic Human Vaccine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Prophylactic Human Vaccine Historic Market Size by Region
  3. 4.2.1 Global Prophylactic Human Vaccine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Prophylactic Human Vaccine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Prophylactic Human Vaccine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Prophylactic Human Vaccine Forecasted Market Size by Region
  7. 4.3.1 Global Prophylactic Human Vaccine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Prophylactic Human Vaccine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Prophylactic Human Vaccine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Prophylactic Human Vaccine by Application
  1. 5.1 Prophylactic Human Vaccine Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Scientific Research
  4. 5.1.3 Others
  5. 5.2 Global Prophylactic Human Vaccine Market Size by Application
  6. 5.2.1 Global Prophylactic Human Vaccine Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Prophylactic Human Vaccine Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Prophylactic Human Vaccine Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Prophylactic Human Vaccine Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Prophylactic Human Vaccine Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Prophylactic Human Vaccine Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Prophylactic Human Vaccine Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Prophylactic Human Vaccine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 GSK
  2. 6.1.1 GSK Company Information
  3. 6.1.2 GSK Business Overview
  4. 6.1.3 GSK Prophylactic Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 GSK Prophylactic Human Vaccine Product Portfolio
  6. 6.1.5 GSK Recent Developments
  7. 6.2 Sanofi
  8. 6.2.1 Sanofi Company Information
  9. 6.2.2 Sanofi Business Overview
  10. 6.2.3 Sanofi Prophylactic Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi Prophylactic Human Vaccine Product Portfolio
  12. 6.2.5 Sanofi Recent Developments
  13. 6.3 Merck
  14. 6.3.1 Merck Company Information
  15. 6.3.2 Merck Business Overview
  16. 6.3.3 Merck Prophylactic Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Merck Prophylactic Human Vaccine Product Portfolio
  18. 6.3.5 Merck Recent Developments
  19. 6.4 Zoetis
  20. 6.4.1 Zoetis Company Information
  21. 6.4.2 Zoetis Business Overview
  22. 6.4.3 Zoetis Prophylactic Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Zoetis Prophylactic Human Vaccine Product Portfolio
  24. 6.4.5 Zoetis Recent Developments
  25. 6.5 Merial
  26. 6.5.1 Merial Company Information
  27. 6.5.2 Merial Business Overview
  28. 6.5.3 Merial Prophylactic Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Merial Prophylactic Human Vaccine Product Portfolio
  30. 6.5.5 Merial Recent Developments
  31. 6.6 McKesson Medical
  32. 6.6.1 McKesson Medical Company Information
  33. 6.6.2 McKesson Medical Business Overview
  34. 6.6.3 McKesson Medical Prophylactic Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 McKesson Medical Prophylactic Human Vaccine Product Portfolio
  36. 6.6.5 McKesson Medical Recent Developments
  37. 6.7 Biovac
  38. 6.7.1 Biovac Company Information
  39. 6.7.2 Biovac Business Overview
  40. 6.7.3 Biovac Prophylactic Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Biovac Prophylactic Human Vaccine Product Portfolio
  42. 6.7.5 Biovac Recent Developments
7 North America by Country
  1. 7.1 North America Prophylactic Human Vaccine Sales by Country
  2. 7.1.1 North America Prophylactic Human Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Prophylactic Human Vaccine Sales by Country (2021-2026)
  4. 7.1.3 North America Prophylactic Human Vaccine Sales Forecast by Country (2027-2032)
  5. 7.2 North America Prophylactic Human Vaccine Market Size by Country
  6. 7.2.1 North America Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Prophylactic Human Vaccine Market Size by Country (2021-2026)
  8. 7.2.3 North America Prophylactic Human Vaccine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Prophylactic Human Vaccine Sales by Country
  2. 8.1.1 Europe Prophylactic Human Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Prophylactic Human Vaccine Sales by Country (2021-2026)
  4. 8.1.3 Europe Prophylactic Human Vaccine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Prophylactic Human Vaccine Market Size by Country
  6. 8.2.1 Europe Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Prophylactic Human Vaccine Market Size by Country (2021-2026)
  8. 8.2.3 Europe Prophylactic Human Vaccine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Prophylactic Human Vaccine Sales by Country
  2. 9.1.1 Asia-Pacific Prophylactic Human Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Prophylactic Human Vaccine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Prophylactic Human Vaccine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Prophylactic Human Vaccine Market Size by Country
  6. 9.2.1 Asia-Pacific Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Prophylactic Human Vaccine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Prophylactic Human Vaccine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Prophylactic Human Vaccine Sales by Country
  2. 10.1.1 South America Prophylactic Human Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Prophylactic Human Vaccine Sales by Country (2021-2026)
  4. 10.1.3 South America Prophylactic Human Vaccine Sales Forecast by Country (2027-2032)
  5. 10.2 South America Prophylactic Human Vaccine Market Size by Country
  6. 10.2.1 South America Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Prophylactic Human Vaccine Market Size by Country (2021-2026)
  8. 10.2.3 South America Prophylactic Human Vaccine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Prophylactic Human Vaccine Sales by Country
  2. 11.1.1 Middle East and Africa Prophylactic Human Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Prophylactic Human Vaccine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Prophylactic Human Vaccine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Prophylactic Human Vaccine Market Size by Country
  6. 11.2.1 Middle East and Africa Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Prophylactic Human Vaccine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Prophylactic Human Vaccine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Prophylactic Human Vaccine Value Chain Analysis
  2. 12.1.1 Prophylactic Human Vaccine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Prophylactic Human Vaccine Production Mode & Process
  7. 12.2 Prophylactic Human Vaccine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Prophylactic Human Vaccine Distributors
  10. 12.2.3 Prophylactic Human Vaccine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst